Issues lobbied + lobbyists (5)
BUD — Budget/Appropriations
Public health program funding Federal research funding Advanced Research Projects Agency for Health (ARPA-H) FY 2026 NIH funding FY 2026 AHRQ funding FY 2026 CDC funding FY 2026 funding for CDC Sickle Cell Data Collection program FY 2026 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program FY 2026 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP) Impact of restructuring and reorganization of federal public health and research agencies Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304 / S. 2587) FY2026 Continuing Appropriations, Agriculture, Leg. Branch & Extensions Act (through 01/30/2026) (H.R. 5371) FY 2026 Consolidated Defense, LHHSED, Nat. Sec.-State, THUD, FSGG Appropriations Act (H.R. 7148) FY 2027 NIH funding FY 2027 AHRQ funding FY 2027 CDC funding FY 2027 funding for CDC Sickle Cell Data Collection program FY 2027 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program FY 2027 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP) FY 2027 Department of Veterans Affairs research funding
Government entities lobbied: Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC); Defense, Dept of (DOD); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Office of Management & Budget (OMB); Office of Science & Technology Policy (OSTP); SENATE; Veterans Affairs, Dept of (VA)
MED — Medical/Disease Research/Clinical Labs
Sickle cell disease/trait issues Hematology/oncology treatment issues Hematology/oncology drug research and approval issues General hematology public health and research issues Open access policy for peer reviewed research journals Women's health and research Issues impacting blood supply shortages/safety Issues impacting delivery of bone marrow, peripheral blood, and cord blood Clinical trials regulations and coverage Issues impacting laboratory testing and pediatric reference intervals (PRIs) Issues impacting drug shortages FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies Issues related to vaccines and immunization practices for individuals with hematologic disorders
Government entities lobbied: Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Defense, Dept of (DOD); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Office of Management & Budget (OMB); Office of Science & Technology Policy (OSTP); President of the U.S.; SENATE; White House Office
MMM — Medicare/Medicaid
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues Issues related to CAR-T/cellular and gene therapies Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries National Coverage Decision for hematopoietic stem cell transplantation (HSCT) for MDS Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Government entities lobbied: Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Social Security Administration (SSA)
HCR — Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Extension of Affordable Care Act enhanced advance premium tax credits Issues related to H-1B visas for physician workforce
Government entities lobbied: Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Homeland Security, Dept of (DHS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE
IMM — Immigration
Issues related to H-1B visas for physician workforce
Government entities lobbied: Homeland Security, Dept of (DHS); HOUSE OF REPRESENTATIVES; SENATE